ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
MOLDXNOV TXNGS MAC NYNOV VS MLDXNGS VS MLDX
2
82233Beta-amyloid; 1-40 (Abeta 40)$93 $130 $93 1.41.0
3
82234Beta-amyloid; 1-42 (Abeta 42)$93 $130 $93 1.41.0
4
83884Neurofilament light chain (NfL)$70 $130 $70 1.81.0
5
84393Tau, phosphorylated (eg, pTau 181, pTau 217), each$88 $130 $88 1.51.0
6
84394 Tau, total (tTau)$88 $130 $88 1.51.0
7
86581Streptococcus pneumoniae antibody (IgG), serotypes, multiplex immunoassay, quantitative$92 $140 $92 1.51.0
8
0020MOncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass$2,500 $3,490 $2,500 1.41.0
9
0420UOncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma $1,018 $1,588 $1,018 1.61.0
10
0422UOncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate $1,943 $3,270 $1,943 1.71.0
11
0425UGenome (e.g., unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (e.g., parents, siblings) $4,094 $7,582 $4,094 1.91.0
12
0426UGenome (e.g., unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis $7,582 $7,582 $7,582 1.01.0
13
0436UOncology (lung), plasma analysis of 388 proteins, using aptamer based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy $712 $1,160 $712 1.61.0
14
0439UCardiology (coronary heart disease [chd]), dna, analysis of 5 single-nucleotide polymorphisms (snps) (rs11716050 [loc105376934], rs6560711 [wdr37], rs3735222 [scin/loc107986769], rs6820447 [intergenic], and rs9638144 [esyt2]) and 3 dna methylation markers (cg00300879 [transcription start site {tss200} of cnksr1], cg09552548 [intergenic], and cg14789911 [body of spatc1l]), qpcr and digital pcr, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic chd$685 $1,050 $685 1.51.0
15
0440UCardiology (coronary heart disease [chd]), dna, analysis of 10 single-nucleotide polymorphisms (snps) (rs710987 [linc010019], rs1333048 [cdkn2b-as1], rs12129789 [kcnd3], rs942317 [ktn1-as1], rs1441433 [ppp3ca], rs2869675 [prex1], rs4639796 [zbtb41], rs4376434 [linc00972], rs12714414 [tmem18], and rs7585056 [tmem18]) and 6 dna methylation markers (cg03725309 [sars1], cg12586707 [cxcl1, cg04988978 [mpo], cg17901584 [dhcr24-dt], cg21161138 [ahrr], and cg12655112 [ehd4]), qpcr and digital pcr, whole blood, algorithm reported as detected or not detected for chd$350 $1,050 $350 3.01.0
16
0441UInfectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index$36 $400 $36 11.01.0
17
0443UNeurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid$70 $130 $70 1.81.0
18
0460UOncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes $917 $760 $917 0.81.0
19
0461UOncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes$917 $911 $917 1.01.0
20
0463UOncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker $150 $760 $150 5.11.0
21
0466UCardiology (coronary artery disease [CAD]), DNA, genome wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease $345 $490 $345 1.41.0
22
0470UOncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma $598 $760 $598 1.31.0
23
0472UCarbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren syndrome$28 $35 $28 1.31.0
24
0478UOncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection$553 $598 $553 1.11.0
25
0483UCarbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren syndrome$28 $35 $28 1.31.0
26
0484UInfectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance$35 $35 $35 1.01.0
27
0485UOncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden$3,649 $3,649 $3,649 1.01.0
28
0486UOncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction$1,644 $3,649 $1,644 2.21.0
29
0489UObstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine the fetal inheritance of the maternal mutation, algorithm reported as a fetal risk score for the condition (e.g., cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)$879 $795 $879 0.91.0
30
0496UOncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk$486 $509 $486 1.01.0
31
0498UOncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation$1,345 $509 $1,345 0.41.0
32
0501UOncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA)$192 $102 $192 0.51.0
33
0508UTransplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphism (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection$2,222 $2,753 $2,222 1.21.0
34
0509UTransplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphism (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection$1,030 $2,735 $1,030 2.71.0
35
0510UOncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype$474 $570 $474 1.21.0
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100